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implantable cardioverter-deﬁbrillator therapy in the MADIT-CRT (Multicenter Automatic Deﬁbrillator Implantation
With Cardiac Resynchronization Therapy) study.Background The impact of carvedilol and metoprolol on inappropriate therapy in heart failure patients with devices has not yet
been investigated.Methods All patients in the MADIT-CRT study who received a device (N ¼ 1,790) were identiﬁed. Using time-dependent Cox
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primary endpoint of inappropriate therapy, delivered as antitachycardia pacing (ATP) or shock therapy. Secondary
endpoints were inappropriate therapy due to atrial ﬁbrillation and atrial tachyarrhythmias, also evaluated as ATP or
shock therapy.Results Inappropriate therapy occurred in 253 (14%) of 1,790 patients during a follow-up period of 3.4  1.1 years.
Treatment with carvedilol was associated with a signiﬁcantly decreased risk of inappropriate therapy compared with
metoprolol (hazard ratio [HR]: 0.64 [95% conﬁdence interval (CI): 0.48 to 0.85]; p ¼ 0.002). The reduction in risk
was consistent for inappropriate ATP (HR: 0.66 [95% CI: 0.48 to 0.90]; p ¼ 0.009) and inappropriate shock therapy
(HR: 0.54 [95% CI: 0.36 to 0.80]; p ¼ 0.002). The risk of inappropriate therapy caused by atrial ﬁbrillation was also
reduced in patients receiving carvedilol compared with metoprolol (HR: 0.50 [95% CI: 0.32 to 0.81]; p ¼ 0.004).
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1344prevent or reduce inappropriate
therapy are warranted, and clin-
ical trials have been undertakenin
attempts to reduce this burden
(7). Carvedilol and metoprolol
are the beta-blockers most com-
monly used in patients with HF.
Carvedilol improves cardiac per-
formance to a greater extent than
metoprolol, and the differences
may be related to carvedilol’s
greater antiadrenergic activity (8).It has previously been shown that carvedilol, compared with
metoprolol, led to an overall signiﬁcant reduction in hospi-
talizations for HF, ventricular arrhythmias (9), and cardio-
vascular deaths (10,11). Current guidelines, however, do
not speciﬁcally comment on issues related to inappropriate
therapy. To our knowledge, the general and individual im-
pact of beta-blockers on the risk of inappropriate ICD therapy
has not yet been investigated.
See page 1351
The goal of the current study was to evaluate the effects of
carvedilol and metoprolol on the endpoint of inappropriate
ICD therapy in the MADIT-CRT (Multicenter Automatic
Deﬁbrillator Implantation With Cardiac Resynchronization
Therapy) study.
We hypothesized that carvedilol would be associated with
a decreased risk of inappropriate therapy due to its greater
antiadrenergic effect.
Methods
MADIT-CRT. The protocol and primary report of the
MADIT-CRT study have previously been published
(12,13). The study included 1,820 patients with ischemic
cardiomyopathy New York Heart Association class I or II,
nonischemic cardiomyopathy New York Heart Association
class II, a left ventricular ejection fraction 30%, and a QRS
duration 130 ms. Patients were enrolled from 110 centers
in the United States, Europe, and Canada and randomized
(3:2) to receive CRT-D and ICD devices.
Patients were excluded if they had atrial ﬁbrillation at
enrollment; a history of atrial ﬁbrillation was not an exclu-
sion criterion. Of the 1,820 patients included in the
MADIT-CRT study, 30 patients (2%) never received a
device, leaving a study population of 1,790 patients.
BETA-BLOCKER THERAPY. Patients had to be on optimal
pharmacotherapy in accordance with HF guidelines (14).
However, the choice of beta-blockers and other HF the-
rapy was left to the discretion of the physician performing
the implantation. All medication, including type of beta-
blocker, and the doses were recorded at baseline andduring clinical follow-up at 1 month and then at 3-month
intervals until termination of the trial.
DEVICE PROGRAMMING AND INTERROGATION. All devices
were programmed according to the prespeciﬁed protocol (13).
The ventricular tachycardia zone was programmed from 180
beats/min up to 250 beats/min, and ventricular ﬁbrillation
was deﬁned as a ventricular rate faster than 250 beats/min
with disorganized ventricular electrograms.
All devices were interrogated 1 month after enrollment and
thereafter every 3 months and adjudicated by an independent
core laboratory for predeﬁned categories of appropriate or
inappropriate therapy.
ENDPOINTS. The primary endpoint of the current study was
deﬁned as occurrence of inappropriate therapy, delivered as
antitachycardia pacing (ATP) or shock therapy, without the
presence of ventricular tachycardia or ventricular ﬁbrillation.
The secondary endpoints were inappropriate therapy for
atrial tachyarrhythmia and inappropriate therapy for atrial
ﬁbrillation and/or atrial ﬂutter. All endpoints of inappro-
priate therapy were secondarily subdivided into inappro-
priate ATP or shock therapy. Last, inappropriate therapy
caused by nonarrhythmic events and other inappropriate
arrhythmic events were investigated (the Online Appendix
provides speciﬁc deﬁnitions).
Statistics. Continuous variables are expressed as mean 
SD. Categorical data are summarized as frequencies and
percentages. As shown in Table 1, patients were divided
into 4 groups based on their beta-blocker use: metoprolol,
carvedilol, other beta-blockers (bisoprolol, atenolol, and
others), or no beta-blockers. Baseline characteristics were
compared between patients by using the chi-square test for
binary variables and the Kruskal-Wallis test for continuous
variables.
Beta-blocker therapy was assessed in the multivariate
model in a time-dependent manner (i.e., by incorporating
into the Cox model, data for each patient that identiﬁes the
effect of each follow-up time “on” and “off” beta-blocker
therapy during the trial). The effects of time-dependent
beta-blocker therapy on the endpoints were assessed with
interaction-term analysis.
Univariate and multivariate time-dependent Cox pro-
portional hazards regression analysis were performed on the
primary and secondary endpoints of inappropriate therapy
and also divided into ATP or shock therapy. In the
multivariate model, we adjusted for relevant variables for
the outcome of inappropriate therapy found by stepwise
selection, setting the limits for entry into the model at
0.05. Five variables were found to have a signiﬁcant impact
on the results (p < 0.05) in the main model on inappro-
priate therapy: previous ventricular arrhythmias, female sex,
QRS duration, use of statins, and diastolic blood pressure.
Results are reported as hazard ratios (HRs) with their 95%
conﬁdence intervals (CIs) and 2-sided p values. The
cumulative probability of inappropriate therapy, ATP, and
shocks were displayed by the Kaplan-Meier method using
Table 1 Baseline Characteristics of the Study Population
Clinical Characteristic No Beta-Blockers Carvedilol Metoprolol Other Beta-Blockers p Value
n 120 (6.7) 1,077 (60.5) 438 (24.6) 146 (8.2)
Female 17 (14) 309 (29) 91 (21) 25 (17) <0.001
CRT-D assigned treatment 71 (59) 637 (59) 275 (63) 89 (61) NS
Dual-chamber ICD 38 (78) 268 (61) 79 (48) 32 (56) <0.001
Age at enrollment (yrs) 69.0  9.4 63.5  11.0 65.0  10.3 65.8  9.8 <0.001
Cardiac history
Ischemic NYHA class I 27 (23) 119 (11) 80 (18) 31 (21) <0.001
Ischemic NYHA class II 50 (42) 393 (36) 208 (47) 67 (46) <0.001
Nonischemic NYHA class II 43 (36) 565 (52) 150 (34) 48 (33) <0.001
Hospitalization in prior year 50 (42) 464 (43) 224 (53) 84 (58) <0.05
Previous hospitalization for heart failure 36 (31) 413 (39) 168 (39) 50 (35) NS
Previous coronary bypass surgery 52 (43) 264 (25) 147 (34) 53 (36) <0.001
Cerebrovascular accident 10 (8) 69 (6) 26 (6) 9 (6) NS
Diabetes 40 (33) 314 (29) 131 (30) 52 (36) NS
Hypertension 67 (56) 659 (61) 303 (69) 100 (68) <0.05
Previous non-CABG revascularization 28 (23) 262 (24) 140 (32) 52 (36) <0.05
Previous MI 57 (49) 393 (37) 226 (53) 83 (59) <0.001
Non-U.S. implanting center 35 (29) 275 (26) 137 (31) 99 (68) NS
Previously smoked 69 (59) 550 (52) 226 (52) 98 (69) NS
Previous atrial arrhythmias 26 (22) 109 (10) 52 (12) 21 (15) <0.001
Previous ventricular arrhythmias 15 (13) 60 (6) 37 (9) 12 (8) <0.05
Medications
Antiarrhythmic use, including amiodarone and sotalol 25 (21) 71 (7) 35 (8) 15 (10) <0.001
ACE Inhibitor or ARB 109 (91) 1,034 (96) 419 (96) 140 (96) <0.05
Aldosterone antagonist 4 (3) 12 (1) 10 (2) 3 (2) NS
Calcium channel blocker 12 (10) 62 (6) 46 (11) 13 (9) NS
Digitalis 23 (19) 303 (28) 111 (25) 21 (14) NS
Diuretic 75 (63) 734 (68) 293 (67) 103 (71) NS
Statins 81 (68) 706 (66) 306 (70) 110 (75) NS
Thrombolytic agent, excluding aspirin 30 (25) 192 (18) 90 (21) 27 (18) NS
Clinical characteristics at enrollment
QRS duration (ms) 159.0  19.0 158.4  19.9 156.5  18.7 160.5  21.9 NS
LBBB 77 (64) 780 (72) 302 (69) 101 (69) NS
RBBB 25 (21) 113 (11) 64 (15) 20 (14) <0.001
Heart rate (beats/min) 68.5  13.2 67.7  10.2 67.8  11.5 67.4  11.5 NS
BMI (kg/m2) 28.3  5.1 28.7  5.3 29.2  5.6 27.4  3.8 NS
BUN (mg/dl) 23.6  9.7 21.2  8.8 21.6  9.1 21.6  8.5 <0.05
Creatinine (mg/dl) 1.31  0.64 1.14  0.32 1.18  0.33 1.14  0.27 <0.001
BNP level 127.5  132.3 125.1  170.4 117.0  131.5 173.6  233.0 NS
Systolic blood pressure (mm Hg) 123.3  17.9 121.7  17.0 123.8  17.5 124.6  18.8 NS
Diastolic blood pressure (mm Hg) 71.9  10.5 71.4  10.3 71.8  10.3 72.6  10.2 NS
Echocardiographic characteristics at enrollment
EF (%) 24.0  4.8 23.6  5.3 23.9  5.2 24.4  4.9 NS
LVEDV (ml) 240.3  51.1 248.4  62.0 249.0  64.7 250.4  57.8 NS
LVEDD (mm) 63.3  4.5 64.0  5.4 63.8  5.4 64.1  4.8 NS
LVESV (ml) 172.7  42.2 177.3  50.1 177.3  52.0 179.1  45.4 NS
LVESD (mm) 53.6  4.8 53.9  5.5 53.7  5.5 54.0  4.7 NS
LAV (ml) 96.0  22.4 93.6  22.1 92.8  21.3 94.8  19.2 NS
Values are n (%) or mean  SD.
ACE ¼ angiotensin-converting enzyme; ARB ¼ angiotensin receptor blocker; BMI ¼ body mass index; BNP ¼ brain natriuretic peptide; BUN ¼ blood urea nitrogen; CABG ¼ coronary artery bypass graft;
CRT-D ¼ cardiac resynchronization device with deﬁbrillator; EF ¼ ejection fraction; ICD ¼ implantable cardioverter-deﬁbrillator; NYHA ¼ New York Heart Association; MI ¼ myocardial infarction; LAV ¼ left
atrium volume; LBBB ¼ left bundle branch block; LVEDD ¼ left ventricular end-diastolic diameter; LVEDV ¼ left ventricular end-diastolic volume; LVESD ¼ left ventricle end-systolic diameter; LVESV ¼ left
ventricle end-systolic volume; RBBB ¼ right bundle branch block.
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p value 0.05 was considered statistically signiﬁcant.
Analyses were performed by using SAS version 9.3 (SAS
Institute, Inc., Cary, North Carolina).Results
A total of 1,790 patients received either ICD or CRT-D; of
these, 1,077 (61%), 438 (24%), 94 (5%), and 40 (2%)
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respectively. Only 12 patients received other beta-blockers,
and a combination of beta-blockers was used in 9 patients.
A total of 120 (7%) patients were not receiving beta-blockers
due to intolerance, asthma, and other causes.
Compared with patients taking carvedilol, metoprolol
was more frequently used in patients of older age, patients
with ischemic cardiomyopathy and hypertension, and in
those who had previously undergone revascularization
(Table 1). Notably, the highest proportion of patients
taking carvedilol were from U.S. centers; the highest users
of bisoprolol (94%) were from non-U.S. centers (data not
shown).
Primary endpoint. Inappropriate therapy occurred in 253
(14%) of 1,790 patients during the follow-up period of 3.4 
1.1 years.Therewas nodifference betweenpatients receiving an
ICD and those who received a CRT-D (p ¼ 0.944).
A univariate comparison of the 4 groups is presented in
Figure 1 showing an overall signiﬁcant difference. Carvedilol
and “other beta-blockers” (composed of bisoprolol and ate-
nolol) are markedly separated from patients taking meto-
prolol. Figures 2 and 3 present the head-to-head comparison
of carvedilol and metoprolol on overall cumulative probability
of inappropriate ATP and inappropriate shock therapy, with
signiﬁcant differences between them. The multivariate time-
dependent Cox regression analysis in Table 2 displays a sig-
niﬁcant relative risk reduction in all inappropriate therapies
associated with the use of carvedilol compared with meto-
prolol (HR: 0.64 [95% CI: 0.48 to 0.85]; p ¼ 0.002). ThisFigure 1 Cumulative Probability of All Inappropriate ICD Therapy Am
The cumulative probability of inappropriate implantable cardioverter-deﬁbrillator (ICD) the
blockers [BB], and no BB). The 4-year cumulative probability of inappropriate therapy amon
of inappropriate ICD therapy among patients receiving metoprolol of 23%. Unadjusted ovﬁnding was consistent and also evident for inappropriate
ATP (HR: 0.66 [95% CI: 0.48 to 0.90]; p ¼ 0.009) and for
inappropriate shocks (HR: 0.54 [95% CI: 0.36 to 0.80]; p ¼
0.002).
Secondary endpoints. Inappropriate therapy caused by
atrial ﬁbrillation occurred in 86 (5%) of 1,790 patients; 16
(19%) of these patients had a history of atrial arrhythmias
requiring treatment.
Table 3 displays the multivariate analysis comparing beta-
blockers. There was a reduction in risk of inappropriate
therapy due to atrial ﬁbrillation in patients treated with car-
vedilol compared with metoprolol (HR: 0.50 [95% CI: 0.32
to 0.81]; p ¼ 0.004). This reduction in risk, however, was
driven primarily by the use of ATP (HR: 0.44 [95% CI: 0.25
to 0.78]; p ¼ 0.005), whereas there was no signiﬁcant
reduction in risk of inappropriate shock therapy for atrial
ﬁbrillation associated with the use of carvedilol. For inap-
propriate therapy for all atrial tachyarrhythmias, a signiﬁcant
risk reduction was associated with the use of carvedilol
regarding both inappropriate ATP and inappropriate shock
therapy compared with metoprolol (Table 4).
Finally, no differences were found in inappropriate the-
rapy for nonatrial tachyarrhythmias in a comparison of the
beta-blockers, and no differences were found for non-
arrhythmic causes of inappropriate therapy (total of 29 and 22
events, respectively [data not shown]).
Doses. The mean doses of beta-blockers at baseline and
after ﬁrst change are shown in Table 5; only minor changes
in dose occurred after the ﬁrst change. Few patients switchedong the 4 Study Groups
rapy differed signiﬁcantly among the 4 groups (metoprolol, carvedilol, other beta-
g patients receiving carvedilol was 14% compared with a 4-year cumulative probability
erall comparison of the 4 groups, p ¼ 0.002.
Figure 2 Cumulative Probability of All Inappropriate ATP Comparing Metoprolol and Carvedilol
The cumulative probability of inappropriate antitachycardia pacing (ATP) differed signiﬁcantly between patients who were treated with carvedilol compared with patients treated
with metoprolol. Unadjusted p ¼ 0.005.
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were taken into account in the time-dependent analyses.
The mean dose increase for carvedilol was higher than for
metoprolol throughout the course of the study, but when
exploring baseline dose-dependent relationships on the
endpoints, we found no clear association. In addition, when
adjusting for baseline and ﬁrst change doses of carvedilolFigure 3 Cumulative Probability of Inappropriate Shock Therapy Com
The cumulative probability of inappropriate shock therapy differed signiﬁcantly between p
Unadjusted p <0.001.dose-equivalents in the Cox regression models, the results
were not altered.
Discussion
The major and novel ﬁnding of the current study was the
signiﬁcant difference in all measured outcomes betweenparing Metoprolol and Carvedilol
atients treated with carvedilol compared with patients treated with metoprolol.
Table 2
Multivariate Cox Regression Analysis for Inappropriate Therapy for
Primary Endpoints







Carvedilol 0.64 0.48–0.85 0.002
Bisoprolol 0.68 0.38–1.22 0.193
Atenolol 0.75 0.28–2.07 0.583
No beta-blocker 1.07 0.66–1.74 0.788
ATP 200
Carvedilol 0.66 0.48–0.90 0.009
Bisoprolol 0.67 0.34–1.30 0.234
Atenolol 0.74 0.23–2.35 0.606
No beta-blocker 1.09 0.64–1.87 0.754
Shock therapy 123
Carvedilol 0.54 0.36–0.80 0.002
Bisoprolol 0.70 0.31–1.56 0.383
Atenolol 0.35 0.05–2.56 0.302
No beta-blocker 1.04 0.53–2.02 0.920
Adjusted for previous ventricular arrhythmias, female sex, QRS duration, statin use, and diastolic blood pressure.
ATP ¼ antitachycardia pacing.
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a signiﬁcant reduction in risk of inappropriate therapy and
remained independently signiﬁcant throughout the study
regarding inappropriate ATP and shock therapy, enforcing
these results. The analysis also found that carvedilol was
signiﬁcantly associated with a reduced risk of inappropriate
therapy for atrial tachyarrhythmias, which was also consistent
when subdivided into ATP and shock therapy. The subdivi-
sion of inappropriate therapy is important to establish that theTable 3
Multivariate Cox Regression An
Atrial Fibrillation
Therapy No. of Events
Inappropriate therapy for atrial












Shock therapy for atrial






Adjusted for previous ventricular arrhythmias, female sex, QRS
ATP ¼ antitachycardia pacing; NA ¼ not available.reduction in risk is not driven by ATP alone but rather by
inappropriate shock therapy and thus is clinically very impor-
tant. Furthermore, the subdivision into atrial tachyarrhythmias
and atrial ﬁbrillation is clinically important and implies that the
reduction in risk associated with the use of carvedilol is not
driven by other nonarrhythmic inappropriate causes.
Although there were signiﬁcant differences at baseline
between the allocated beta-blocker groups, factors clinically


















duration, statin use, and diastolic blood pressure.
Table 4
Multivariate Cox Regression Analysis for Inappropriate Therapy for
Atrial Tachyarrhythmias






Inappropriate therapy for AT 201
Carvedilol 0.64 0.47–0.88 0.006
Bisoprolol 0.68 0.35–1.33 0.262
Atenolol 0.49 0.12–1.99 0.314
No beta-blocker 1.17 0.69–1.98 0.561
ATP for AT 163
Carvedilol 0.62 0.44–0.88 0.007
Bisoprolol 0.65 0.31–1.37 0.257
Atenolol 0.59 0.14–2.44 0.469
No beta-blocker 1.07 0.59–1.94 0.816
Shock therapy for AT 95
Carvedilol 0.58 0.37–0.92 0.020
Bisoprolol 0.85 0.35–2.05 0.720
Atenolol NA NA NA
No beta-blocker 1.33 0.65–2.73 0.437
Adjusted for past ventricular arrhythmias, female sex, QRS duration, statin use, and diastolic blood pressure.
AT ¼ atrial tachyarrhythmia; other abbreviations as in Table 3.
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analysis. This point is very important, and factors associated
with increased risk of death or hospitalizations as a whole are
not necessarily the same as the factors associated with inap-
propriate therapy. Previous studies have shown similar clin-
ically relevant covariates as our model selected, in which
primarily the nonuse of statins, previous ventricular or atrial
arrhythmias, younger age, and male sex are considered risk
factors for development of inappropriate therapy (3,6,15–17).
In the current study, carvedilol, in doses comparable to
metoprolol as well as in real-life doses, was associated with
a signiﬁcant reduction in inappropriate therapy. One previous
study was underpowered to show a signiﬁcant effect of beta-
blockers on inappropriate therapy (18), and other studies have
generally only compared beta-blockers versus other antiar-
rhythmic agents. Thus, no previous comparison of different
beta-blockers has been undertaken on this clinically impor-
tant endpoint. Amiodarone and sotalol are drugs associated
with wide adverse effects, and preferably any beta-blocker
with an optimal impact on appropriate and inappropriate
therapy should be the ﬁrst choice for treatment, particularly
because beta-blockers are standard therapy for HF. This,Table 5
Doses of Beta-Blockers Used at Baseline and





First Change p Value
Carvedilol 18  13 30  20 <0.001
Metoprolol 66  48 78  54 <0.001
Metoprolol as
carvedilol equivalents
16  12 20  14 <0.001
Bisoprolol 5.4  3.8 5.3  5.3 0.041
Atenolol 34  18 39  25 0.13
Values are mean  SD (in mg).along with previous results (9), suggests that carvedilol may be
the drug of choice in HF patients with implanted devices.
We found that the relative doses of beta-blockers used in
the MADIT-CRT study were comparable to those used
in real-life scenarios of HF patients, supported by numerous
previous nonrandomized or observational studies reporting
the mean doses of beta-blockers (19–21). Hypothesized
factors associated with reduced risk of inappropriate therapy
in patients treated with carvedilol may be differences in the
adrenergic receptor selectivity and ancillary properties.
Metoprolol acts selectively on beta1-receptors, and carvedilol
blocks all 3 adrenergic receptors (alpha1, beta1, and beta2)
implicated in facilitating harmful effects of catecholamines
on the heart. Carvedilol decreases levels of cardiac norepi-
nephrine and suppresses beta-receptors, whereas metoprolol
increases catecholamines and enhances the sensitivity of the
heart to beta-receptor stimulation. These actions may help
explain, in part, the electrophysiological differences between
carvedilol and metoprolol in the current study and may
be due to different effects at the cellular level (8,22,23).
Furthermore, a meta-analysis has indicated a greater increase
in left ventricular ejection fraction in patients with HF
treated with carvedilol (24).
Study limitations. This was a retrospective, nonrandomized
post hoc study. Although multivariate analysis showed that
carvedilol was superior to metoprolol when taking many
confounders into consideration, it was not a prospective
randomized trial comparing thesedrugs, andother confounders
not included in the analyses may have biased our results. An
adjusted multivariate analysis was performed, taking into
account many confounders associated with inappropriate
therapy and those that played a signiﬁcant role on this outcome
in our population. Our study patients were, on average, not
receiving recommended doses of beta-blocker therapy and thus
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reﬂect real-life scenarios of patients with HF.
Conclusions
In patients with mildly symptomatic HF with either a
CRT-D or ICD device, carvedilol was associated with a 36%
reduction in inappropriate ATP and shock therapy compared
with patients taking metoprolol. Inappropriate therapy due to
atrial ﬁbrillation was reduced by 50% in patients taking car-
vedilol compared with metoprolol. Further prospective
studies are needed to conﬁrm these results.
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